mRNA
Coverage of mRNA in the Nexus archive.
- STAT+: Talawar bets bispecific approach can shake up eczema market
Talawar is leveraging a bispecific approach to potentially disrupt the eczema market. The article also highlights a SPAC for a bispecific maker, Moderna's advancing mRNA ambitions, and Clive Meanwell's perspective on AI's role in biotech drug design.
- STAT+: Moderna co-founder Kenneth Chien on the future of mRNA — and Moderna
Kenneth Chien, a co-founder of Moderna, received an Hermes belt from CEO Stéphane Bancel after securing a partnership with AstraZeneca. This deal accelerated Moderna's growth, leading to significant funding and the development of mRNA-based Covid vaccines, though the planned drugs for cancer and cardiovascular disease did not materialize.
- FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
FDA advisors unanimously voted to approve Moderna's mRNA vaccine following internal agency drama. The approval represents a key regulatory decision for the company's vaccine development.
- STAT+: AI titans push Congress for DNA safeguards
Jakob Uszkoreit, co-creator of the transformer architecture behind ChatGPT, is leading Inceptive Nucleics to develop biological foundation models for RNA interference, mRNA, and antisense drugs. The article also mentions ongoing discussions in Congress about DNA safeguards, though the primary focus is on biotech advancements.